1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Chronic Illness in 21 studies
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the effect of the novel intracellular calcium antagonist fasudil hydrochloride, cerebral blood flow (CBF) was measured quantitatively with positron emission tomography following the intravenous administration of fasudil in five patients with chronic cerebral infarction." | 9.07 | Effects of fasudil hydrochloride on cerebral blood flow in patients with chronic cerebral infarction. ( Hatazawa, J; Hirata, Y; Kanno, I; Kondoh, Y; Nagata, K; Satoh, Y; Shishido, F; Watahiki, Y; Yokoyama, E; Yuya, H, 1993) |
| "To evaluate the effect of the novel intracellular calcium antagonist fasudil hydrochloride, cerebral blood flow (CBF) was measured quantitatively with positron emission tomography following the intravenous administration of fasudil in five patients with chronic cerebral infarction." | 5.07 | Effects of fasudil hydrochloride on cerebral blood flow in patients with chronic cerebral infarction. ( Hatazawa, J; Hirata, Y; Kanno, I; Kondoh, Y; Nagata, K; Satoh, Y; Shishido, F; Watahiki, Y; Yokoyama, E; Yuya, H, 1993) |
| "To investigate the effect of fasudil, a Rho-kinase inhibitor, on chronic ischemia-related bladder dysfunction." | 3.88 | Protective Effect of a Rho-kinase Inhibitor on Bladder Dysfunction in a Rat Model of Chronic Bladder Ischemia. ( Aikawa, K; Akaihata, H; Haga, N; Hata, J; Ishibashi, K; Koguchi, T; Kojima, Y; Kushida, N; Matsuoka, K; Nomiya, M, 2018) |
| "Fasudil treatment notably ameliorated ADR-induced cardiac damage, restored heart function, suppressed cell apoptosis and senescence, ameliorated redox imbalance, and DNA damage." | 1.56 | Rho Kinase Inhibition by Fasudil Attenuates Adriamycin-Induced Chronic Heart Injury. ( Miao, D; Xiang, C; Yan, Y; Yang, Z; Zhang, D, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.76) | 18.7374 |
| 1990's | 4 (19.05) | 18.2507 |
| 2000's | 6 (28.57) | 29.6817 |
| 2010's | 8 (38.10) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Yan, Y | 1 |
| Xiang, C | 1 |
| Yang, Z | 1 |
| Miao, D | 1 |
| Zhang, D | 2 |
| Detter, MR | 1 |
| Shenkar, R | 1 |
| Benavides, CR | 1 |
| Neilson, CA | 1 |
| Moore, T | 1 |
| Lightle, R | 1 |
| Hobson, N | 1 |
| Shen, L | 1 |
| Cao, Y | 1 |
| Girard, R | 1 |
| Griffin, E | 1 |
| Gallione, CJ | 1 |
| Awad, IA | 1 |
| Marchuk, DA | 1 |
| Chan, SL | 1 |
| Cipolla, MJ | 1 |
| Akaihata, H | 1 |
| Nomiya, M | 1 |
| Matsuoka, K | 1 |
| Koguchi, T | 1 |
| Hata, J | 1 |
| Haga, N | 1 |
| Kushida, N | 1 |
| Ishibashi, K | 1 |
| Aikawa, K | 1 |
| Kojima, Y | 1 |
| Huang, L | 2 |
| Zhao, LB | 1 |
| Yu, ZY | 1 |
| He, XJ | 1 |
| Ma, LP | 1 |
| Li, N | 1 |
| Guo, LJ | 1 |
| Feng, WY | 1 |
| Zhao, PJ | 1 |
| Pan, J | 1 |
| Li, F | 1 |
| Sun, K | 1 |
| Jawad, E | 1 |
| Arora, R | 1 |
| Ziino, AJ | 1 |
| Ivanovska, J | 2 |
| Belcastro, R | 1 |
| Kantores, C | 2 |
| Xu, EZ | 2 |
| Lau, M | 1 |
| McNamara, PJ | 2 |
| Tanswell, AK | 1 |
| Jankov, RP | 2 |
| Yoshimi, E | 1 |
| Kumakura, F | 1 |
| Hatori, C | 1 |
| Hamachi, E | 1 |
| Iwashita, A | 1 |
| Ishii, N | 1 |
| Terasawa, T | 1 |
| Shimizu, Y | 1 |
| Takeshita, N | 1 |
| Engelberts, D | 1 |
| Kavanagh, BP | 1 |
| Blood, AB | 1 |
| Terry, MH | 1 |
| Merritt, TA | 1 |
| Papamatheakis, DG | 1 |
| Blood, Q | 1 |
| Ross, JM | 1 |
| Power, GG | 1 |
| Longo, LD | 1 |
| Wilson, SM | 1 |
| Haack, KK | 1 |
| Gao, L | 1 |
| Schiller, AM | 1 |
| Curry, PL | 1 |
| Pellegrino, PR | 1 |
| Zucker, IH | 1 |
| Satoh, Si | 1 |
| Ikegaki, I | 2 |
| Toshima, Y | 1 |
| Watanabe, A | 1 |
| Asano, T | 3 |
| Shimokawa, H | 2 |
| Nagaoka, T | 1 |
| Fagan, KA | 1 |
| Gebb, SA | 1 |
| Morris, KG | 1 |
| Suzuki, T | 1 |
| McMurtry, IF | 1 |
| Oka, M | 1 |
| Guilluy, C | 1 |
| Sauzeau, V | 1 |
| Rolli-Derkinderen, M | 1 |
| Guérin, P | 1 |
| Sagan, C | 1 |
| Pacaud, P | 1 |
| Loirand, G | 1 |
| He, Z | 1 |
| Guo, L | 1 |
| Wang, H | 1 |
| Chida, M | 1 |
| Voelkel, NF | 1 |
| Nagata, K | 1 |
| Kondoh, Y | 1 |
| Satoh, Y | 1 |
| Watahiki, Y | 1 |
| Yokoyama, E | 1 |
| Yuya, H | 1 |
| Hirata, Y | 1 |
| Shishido, F | 1 |
| Hatazawa, J | 1 |
| Kanno, I | 1 |
| Almeida, CA | 1 |
| Romano-Silva, MA | 1 |
| Goes, AM | 1 |
| Matsui, T | 1 |
| Sugawa, M | 1 |
| Johshita, H | 1 |
| Takuwa, Y | 1 |
| Shibuya, M | 1 |
| Suzuki, Y | 1 |
| Takayasu, M | 1 |
| Harada, T | 1 |
| Satoh, S | 1 |
| Hidaka, H | 1 |
1 review available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Chronic Illness
| Article | Year |
|---|---|
Chronic stable angina pectoris.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acetanilides; Angina Pectoris; Antihypertensive Agent | 2008 |
1 trial available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Chronic Illness
| Article | Year |
|---|---|
Effects of fasudil hydrochloride on cerebral blood flow in patients with chronic cerebral infarction.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Blood Pressure; Calcium Channel Blockers; Cereb | 1993 |
19 other studies available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Chronic Illness
| Article | Year |
|---|---|
Rho Kinase Inhibition by Fasudil Attenuates Adriamycin-Induced Chronic Heart Injury.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antioxidants; Apoptosis; Biomarkers; Cardiot | 2020 |
Novel Murine Models of Cerebral Cavernous Malformations.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acute Disease; Animals; Apoptosis Regulatory Proteins | 2020 |
Treatment with low dose fasudil for acute ischemic stroke in chronic hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cerebrovascular Circulation; Chronic Disease | 2017 |
Protective Effect of a Rho-kinase Inhibitor on Bladder Dysfunction in a Rat Model of Chronic Bladder Ischemia.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Chronic Disease; Disease Models, Animal; Isc | 2018 |
Long-term inhibition of Rho-kinase restores the LTP impaired in chronic forebrain ischemia rats by regulating GABAA and GABAB receptors.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Ischemia; Chronic Disease; Disease Mod | 2014 |
[Effects of chronic hypoxia on the expression of calmodulin and calcicum/calmodulin-dependent protein kinase II and the calcium activity in myocardial cells in young rats].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blotting, Western; Calcium; Calcium-Calmodul | 2008 |
Effects of rho-kinase inhibition on pulmonary hypertension, lung growth, and structure in neonatal rats chronically exposed to hypoxia.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Airway Remodeling; Amides; Animals; Animals, Newborn; | 2010 |
Antinociceptive effects of AS1892802, a novel Rho kinase inhibitor, in rat models of inflammatory and noninflammatory arthritis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Analgesics; Analgesics, Opioid; Animals; Anti-Inflamm | 2010 |
Rescue treatment with a Rho-kinase inhibitor normalizes right ventricular function and reverses remodeling in juvenile rats with chronic pulmonary hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Age Factors; Aging; Amides; Animals; Apoptosis; Cell | 2010 |
Effect of chronic perinatal hypoxia on the role of rho-kinase in pulmonary artery contraction in newborn lambs.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Altitude; Animals; Animals, Newborn; Arterial Pressur | 2013 |
Central Rho kinase inhibition restores baroreflex sensitivity and angiotensin II type 1 receptor protein imbalance in conscious rabbits with chronic heart failure.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Baroreflex; Brain Stem; Chronic Disease; Con | 2013 |
Effects of Rho-kinase inhibitor on vasopressin-induced chronic myocardial damage in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cardiomyopathies; Chronic Disease; Disease M | 2002 |
Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Inhalation; Administration, Oral; Ami | 2005 |
Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Animals; Carrier Proteins; Chronic Disease; C | 2005 |
Improvement of cognitive deficit and neuronal damage in rats with chronic cerebral ischemia via relative long-term inhibition of rho-kinase.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Infarction; Brain Ischemia; Cerebral C | 2008 |
Effects of acute and chronic hypoxia on rat lung cyclooxygenase.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acute Disease; Animals; Blotting, Northern; Chronic D | 1996 |
Inhibition of protein kinases prevents lymphocyte activation by Schistosoma mansoni antigens and reduces in vitro [correction of in vivo] granuloma reaction.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antigens, Helminth; Calcium; Cell Division; | 1998 |
Activation of the protein kinase C-mediated contractile system in canine basilar artery undergoing chronic vasospasm.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Basilar Artery; Chronic Disease; Dinoprost; | 1991 |
The effects of an intracellular calcium antagonist HA 1077 on delayed cerebral vasospasm in dogs.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Arteries; Calcium Channel Blockers; Cerebral | 1988 |